Results for prescription drug pricing

Health care advocates and researchers testified on prescription drugs costs before the Senate Health, Education, Labor, and Pensions Committee. ... Topics included the role of pharmacy benefit managers (PBMs) in drug pricing, use of the patent system, value-based drug pricing, and competition with generic drug makers.

"We are aware of the many important lifesaving drugs that your companies have produced ... but I think as all of you know, those drugs mean nothing to anybody who cannot afford it," said Senate Health, Education, Labor, and Pensions Committee Chair Bernie Sanders (I-VT) as CEOs from Johnson & Johnson, Merck, and Bristol Myers Squibb testified on the cost of prescription drugs. Topics included drug pricing in the U.S. versus other countries, patents and competition with generic companies, and transparency in pricing from drug distributors.

The committee questioned the witnesses on drug pricing tactics and asked for transparency from the industry. Topics included stock buybacks for pharmaceutical companies, patient assistance programs for uninsured consumers, competitiveness in the market, and lowering the price of prescription drugs overall.

Avik Roy, president of the Foundation for Research on Equal Opportunity, talked about the Inflation Reduction Act's potential impact on prescription drug prices.

Erin Durkin talked about Senate Democrats' prescription drug reform bill.

STAT News' Rachel Cohrs discussed efforts by Congress and the Biden administration to address rising prescription drug costs.

Erin Trish, associate director of the Schaeffer Center at the University of Southern California, talked about the findings of a study that compared spending on common generic drugs by Medica…

Richard Gonzalez, CEO of AbbVie, testified before the House Oversight and Reform Committee on drug prices for two of the company's products, Humira and Imbruvica Humira is used to treat rheumatoid arthritis and other conditions, and Imbruvica is a chemotherapy drug for cancer treatment. ... Other health policy experts also testified on drug costs in the U.S. and offered recommendations on how to make them more affordable.

Country President Thomas Kendris, and Mallinckrodt Pharmaceuticals CEO Mark Trudeau testified on prescription drug pricing before the House Oversight and Reform Committee. ... The drug makers defended the price hikes as the cost of doing research and development and talked about price-reduction programs that their companies offer.

Giovanni Caforio, Teva CEO Kare Schultz and former Celgene CEO Mark Alles testified on prescription drug pricing before the House Oversight and Reform Committee. ... The drug makers defended the price hikes as the cost of doing research and development and talked about price-reduction programs that their companies offer.

Representative Kurt Schrader (D-OR) talked about prescription drug pricing and surprise medical billing legislation.

He outlined legislative priorities for the new session that included increased funding for education, school safety, transparency in prescription drug pricing, investment in infrastructure and roads, and protecting the environment.

Erik Wasson talked about the congressional agenda for the upcoming week, which includes a House Democratic prescription drug pricing bill, possible votes on the U.S.

Representative Michael Burgess (R-TX) talked about the impeachment inquiry and prescription drug pricing legislation.

Representative Peter Welch (D-VT) talked about the House impeachment inquiry of President Trump and prescription drug pricing legislation.

The Senate Judiciary Committee held a hearing on the role of intellectual property in the pricing of prescription drugs. Witnesses included pharmaceutical executives, academic scholars, and state health care officials who testified on the rising costs of prescription drugs, concerns over efforts to delay or deter competition, access to generic drugs, and comparisons between drug prices in the U.S. and in Europe and Canada.

Hearings to examine drug pricing in America, focusing on a prescription for change, part III.

Following a short recess, committee members voted on nearly 30 amendments which addressed such issues as tax reform, border security, housing affordability, disaster relief, agriculture programs and prescription drug pricing.

Members voted on nearly 30 amendments that addressed such issues as tax reform, border security, housing affordability, disaster relief, agriculture programs, and prescription drug pricing.

Chief executive officers from seven prescription drug companies testified before the Senate Finance Committee on drug pricing practices. ... Senator Bob Menendez (D-NJ) warned them, however, that there was bipartisan support to ensure drug prices were brought down, and said that if the companies did not address the issue themselves, Congress or President Trump would take action to force them to do so.